Myelomeningocele
Methodology & AI Transparency ⓘ
Myelomeningocele Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as Q05.9, Myelomeningocele falls under Pediatrics management, where family-centered specialist care [Myelomeningocele Q05.9] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Myelomeningocele uses ICD-10 Q05.9 across Pediatrics specialty care.
- 3 Typical cash cost range: Workup highlights for Myelomeningocele (Q05.9): family-centered specialist care [Myelomeningocele Q05.9].
- 4 Top reported side effects / signs: Key Pediatrics biomarkers for Myelomeningocele (Q05.9): Pediatric Hemoglobin & in Myelomeningocele (Q05.9: Lead Screen) & WHO / CDC in Myelomeningocele (Q05.9: Age-Adjusted Growth Percentiles) (Consistent personal growth curve tracking (Q05.9)).
Ask our AI Specialists anything about Myelomeningocele
What Is Myelomeningocele?
Designated in federal medical registries as Q05.9, Myelomeningocele falls under Pediatrics management, where family-centered specialist care [Myelomeningocele Q05.9] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Myelomeningocele (Q05.9, Pediatrics) reflects early intervention timing [Myelomeningocele Q05.9]. longitudinal control is benchmarked via Pediatric Hemoglobin & in Myelomeningocele (Q05.9: Lead Screen).
Common Symptoms & Clinical Signs
- • Presentation of Myelomeningocele (Q05.9): growth velocity shifts, in Myelomeningocele (Q05.9: newborn feeding/jaundice signs,)
- • Secondary Myelomeningocele clinical sign: acute childhood fever, in Myelomeningocele (Q05.9: barking cough, wheezing,)
- • Symptom flares in Myelomeningocele correlating with Pediatric Hemoglobin & in Myelomeningocele (Q05.9: Lead Screen) deviation outside Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q05.9)
- • Functional pediatrics impact requiring family-centered specialist care [Myelomeningocele Q05.9] evaluation (Q05.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Myelomeningocele Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q05.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Children's & Adolescent Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pediatric Hemoglobin & in Myelomeningocele (Q05.9: Lead Screen) | Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q05.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: WHO / CDC in Myelomeningocele (Q05.9: Age-Adjusted Growth Percentiles) | Consistent personal growth curve tracking (Q05.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Myelomeningocele
Treatment selection for Myelomeningocele depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Myelomeningocele)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Bacterial Mucosal Immunotherapy with MV130 Prevents Recurrent Wheezing in Objectives: To evaluate the real-world benefits and safety of mucosal sublingual immunotherapy based on whole inactivated bacteria (MV130) in preventing WA in children. American journal of respiratory and critical care medicine • 2021-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 33705665 ↗ |
| Can This Approach Help? Inside the Latest Research on Dosing Regimen Prediction and Confirmation With Rivaroxaban for A body weight-based dose regimen selected by physiologically based how the body absorbs the medicine modeling was shown in the UNIVERSE study to be appropriate for thromboprophylaxis in the post-Fontan children population. Journal of clinical pharmacology • 2022-02-15 • Phase III Randomized Trial | N = 12 | 82/100 | PMID 34524700 ↗ |
Myelomeningocele Patient Community & “People Like Me” Threads
Filter Myelomeningocele community threads and patient logs by age, biological sex, dosage, and treatment duration.